Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B

doi:10.3969/j.issn.1006-7795.2018.06.004

Abstract

Abstract: Objective To investigate the effect of antivirals therapy combined with traditional Chinese medicine therapy on hepatitis B e antigen (HBeAg) seroconversion rate in patients with HBeAg-positive chronic hepatitis B. Methods The 679 HBeAg-positive chronic hepatitis B patients who met the inclusion criteria were divided into the antiviral western medicine group (209 patients) and the Chinese and western medicine combination group (470 patients) according to whether or not they were treated with traditional Chinese medicine. The HBeAg seroconversion rate was observed after 1 year of treatment, and stratified sampling was applied to identify the dominant population of combined therapy. Results After 1 year of the treatment, the seroconversion rate of HBeAg in the antiviral western medicine group and the combined group was 11.5% and 12.8%, respectively, with P=0.66. The patients were scored with the scoring model that our group established in the early stage. For those patients with a score of 0-1 in the antiviral western medicine group and combined therapy group,HBeAg conversion rates were 2.6% and 8.1%, respectively, with P=0.04. Conclusion On the basis of antiviral treatment, combined Chinese medicine treatment can improve the HBeAg seroconversion rate of chronic hepatitis B patients with a score of 0-1.

Key words: chronic hepatitis B, hepatitis B e antigen seroconversion, antiviral therapy, scoring model, Chinese medicine treatment, combination therapy

CLC Number:

R575.1

Geng Mingfan, Gao Fangyuan, Li Yuxin, Zhang Qun, Liu Yao, Wang Xianbo. Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B[J]. Journal of Capital Medical University, 2018, 39(6): 810-814.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.06.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I6/810

References

[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):383-403.
[2] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志,2015,9(5):1-17.
[3] Piratvisuth T. Reviews for APASL guidelines:immunomodulator therapy of chronic hepatitis B[J].Hepatol Int,2008, 2(2):140-146.
[4] Lau G K, Wang F S.Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion:a need for more translational study[J].J Hepatol,2012, 56(4):753-755.
[5] Liaw Y F, Kao J H, Piratvisuth T, et al. Asian-pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J]. Hepatol Int,2012, 6(3):531-561.
[6] Fattovich G, Brollo L, Giustina G,et al.Natural history and prognostic factors for chronic hepatitis type B[J].Gut,1991,32(3):294-298.
[7] Lin B, Ha N B, Liu A, et al.Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos (t) ides in routine practice[J].J Gastroenterol Hepatol,2013,28(5):855-860.
[8] Fried M W, Piratvisuth T, Lau G K, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology, 2008, 47(2):428-434.
[9] Li X, Wang Y, Han D, et al. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B[J]. Hepatol Res, 2014, 44(2):187-193.
[10] Chi H, Bömmel F V, Buti M, et al. P0661:Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count:Results from a large european multi-center study[J]. J Hepatol, 2015, 62(422):S568.
[11] Wang J, Du L Y, Zhu X, et al. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks[J]. Indian J Med Microbiol, 2015,33 Suppl:20-25.
[12] Huang R, Yang C C, Liu Y, et al. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients[J].World J Gastroenterol,2015,21(34):9957-9965.
[13] Geng M, Li Y X, Gao F Y, et al. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogues:real-world clinical practice[J]. Int J Infect Dis, 2017, 62:18-25.
[14] Hui C K, Leung N, Shek T W, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients[J]. Hepatology, 2007, 46(3):690-698.
[15] 王传敏, 柯昌征, 张银华,等. 扶正化瘀胶囊联合阿德福韦酯治疗慢性乙型肝炎的疗效及对免疫功能和肝功能的影响[J]. 现代中西医结合杂志, 2015,24(15):1618-1620.
[16] 杨琴, 马臻. 复方鳖甲软肝片联合恩替卡韦治疗对慢性乙肝患者肝纤维化进程及免疫应答状态的影响[J]. 海南医学院学报, 2018,24(5):593-596.
[17] 张俊婷, 安和兵. 阿德福韦酯联合九味肝泰治疗对儿童慢性乙型肝炎患者T细胞亚群及肝纤维化指标的影响[J]. 安徽医学, 2018(5):537-540.
[18] 仇君, 何荣芬, 高亮. 茵栀黄口服液在免疫性肝损伤中的作用研究[J]. 中国药房, 2010,21(27):2510-2512.
[19] 赵长青, 徐列明. 扶正化瘀胶囊/片治疗肝纤维化和肝硬化的临床研究进展[J]. 世界中医药, 2014,9(5):561-567.
[20] Deng X, Liang J, Liu Z W, et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis[J]. Chin J Integr Med, 2013, 19(4):289-296.
[21] 段雪琳, 黎桂玉, 李树民,等. 复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析[J]. 中国医院药学杂志, 2015, 35(19):1762-1765.
[22] 夏晖, 张宁, 周双男,等. 复方鳖甲软肝片抗肝纤维化研究进展[J]. 医药导报, 2013, 32(4):500-503.